Literature DB >> 9092098

[Measles vaccination by the aerosol method in Mexico].

J Fernández-de Castro1, J Kumate-Rodríguez, J Sepúlveda, J M Ramírez-Isunza, J L Valdespino-Gómez.   

Abstract

The present work describes the anti-measles vaccination program by the inhaled aerosol method undertaken in Mexico between 1988 and 1990. Detailed descriptions are given of the equipment, staff, training programs, promotion and campaigns. The vaccine is specified: Edmonston-Zagreb strain cultured in diploid cells at the Instituto Nacional de Virología of the Secretaría de Salud in Mexico with titres varying from 1045 plaque forming units (PFU/ml) to 1048 PFU/ml administered in a 30 sec inhalation with aerosol. During this exposure period, 2800 to 4000 PFU per child are estimated to enter the child, of which approximately 25% is the retained doses, i.e. 700 to 1000 PFU/child. A total of 3760684 children of school and pre-school age have been vaccinated in 13 of the 32 federal entities of the country. No undesirable effects of any importance were observed, and the limited serological and field studies support the effectiveness and security of this method. On the other hand, the method is much cheaper, faster and better accepted by the population than the subcutaneous injection.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9092098

Source DB:  PubMed          Journal:  Salud Publica Mex        ISSN: 0036-3634


  7 in total

1.  The Reemergence of Measles.

Authors:  C L Abad; N Safdar
Journal:  Curr Infect Dis Rep       Date:  2015-12       Impact factor: 3.725

2.  Increasing the time of exposure to aerosol measles vaccine elicits an immune response equivalent to that seen in 9-month-old Mexican children given the same dose subcutaneously.

Authors:  Rosa María Wong-Chew; Miguel Leonardo García-León; Bogart Espinosa-Torres Torrija; Brenda Hernández-Pérez; Lino E Cardiel-Marmolejo; Judy A Beeler; Susette Audet; José Ignacio Santos-Preciado
Journal:  J Infect Dis       Date:  2011-08-01       Impact factor: 5.226

3.  Mucosal parainfluenza virus-vectored vaccine against Ebola virus replicates in the respiratory tract of vector-immune monkeys and is immunogenic.

Authors:  Alexander A Bukreyev; Joshua M Dinapoli; Lijuan Yang; Brian R Murphy; Peter L Collins
Journal:  Virology       Date:  2010-02-02       Impact factor: 3.616

4.  Newcastle disease virus-vectored vaccines expressing the hemagglutinin or neuraminidase protein of H5N1 highly pathogenic avian influenza virus protect against virus challenge in monkeys.

Authors:  Joshua M DiNapoli; Baibaswata Nayak; Lijuan Yang; Brad W Finneyfrock; Anthony Cook; Hanne Andersen; Fernando Torres-Velez; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2009-11-18       Impact factor: 5.103

Review 5.  An evaluation of respiratory administration of measles vaccine for prevention of acute lower respiratory infections in children.

Authors:  Daisy Higginson; Evropi Theodoratou; Harish Nair; Tanvir Huda; Lina Zgaga; Suresh S Jadhav; Saad B Omer; Igor Rudan; Harry Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

6.  Priming T-cell responses with recombinant measles vaccine vector in a heterologous prime-boost setting in non-human primates.

Authors:  Diane L Bolton; Sampa Santra; Cindy Swett-Tapia; Jerome Custers; Kaimei Song; Harikrishnan Balachandran; Linh Mach; Hussein Naim; Pamela A Kozlowski; Michelle Lifton; Jaap Goudsmit; Norman Letvin; Mario Roederer; Katarina Radošević
Journal:  Vaccine       Date:  2012-06-22       Impact factor: 3.641

7.  Aerosol prime-boost vaccination provides strong protection in outbred rabbits against virulent type A Francisella tularensis.

Authors:  Katherine J O'Malley; Jennifer D Bowling; Elizabeth Stinson; Kelly S Cole; Barbara J Mann; Prachi Namjoshi; Karsten R O Hazlett; Eileen M Barry; Douglas S Reed
Journal:  PLoS One       Date:  2018-10-22       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.